| Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging (NCT06632912) | National Vaccine and Serum Institute, China | 2025-11-21 |
| Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula Polymorpha) (NCT05916326) | National Vaccine and Serum Institute, China | 2023-06-30 |
| Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial (NCT05599516) | National Vaccine and Serum Institute, China | 2022-11-04 |
| Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above (NCT05408312) | National Vaccine and Serum Institute, China | 2022-06-18 |
| A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years (NCT05262010) | National Vaccine and Serum Institute, China | 2022-06-04 |
| A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell) (NCT05293548) | National Vaccine and Serum Institute, China | 2022-05-25 |
| Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above (NCT05069129) | National Vaccine and Serum Institute, China | 2021-10-14 |
| Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above (NCT05033847) | National Vaccine and Serum Institute, China | 2021-09-12 |
| Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha) (NCT04941261) | National Vaccine and Serum Institute, China | 2021-06-30 |
| A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19 (NCT04869592) | National Vaccine and Serum Institute, China | 2021-04-25 |
| Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) (NCT04436133) | National Vaccine and Serum Institute, China | 2020-06-20 |
| A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent Vaccine (NCT04188691) | National Vaccine and Serum Institute, China | 2019-11-28 |
| A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years (NCT04083196) | National Vaccine and Serum Institute, China | 2019-09-07 |